Patents Represented by Attorney Dean G. Stathakis
-
Patent number: 7833535Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: GrantFiled: October 26, 2007Date of Patent: November 16, 2010Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 7825233Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.Type: GrantFiled: June 9, 2005Date of Patent: November 2, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Marcella A. Gilmore, Ester G. Fernandez-Salas, Shengwen Li, Ronald G. Miller, Kei Roger Aoki
-
Patent number: 7645570Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.Type: GrantFiled: March 13, 2008Date of Patent: January 12, 2010Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
-
Patent number: 7638294Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.Type: GrantFiled: May 21, 2008Date of Patent: December 29, 2009Assignee: Allergan, Inc.Inventors: Dudley J. Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Roger Aoki
-
Patent number: 7635484Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: December 22, 2009Assignees: Allergan, Inc., Baylor College of MedicineInventor: M. Zouhair Atassi
-
Patent number: 7635574Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.Type: GrantFiled: May 22, 2008Date of Patent: December 22, 2009Assignee: Allergan, Inc.Inventors: Dudley J. Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Roger Aoki
-
Patent number: 7632655Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.Type: GrantFiled: May 22, 2008Date of Patent: December 15, 2009Assignee: Allergan, Inc.Inventors: Dudley J. Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Roger Aoki
-
Patent number: 7622127Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: GrantFiled: June 20, 2007Date of Patent: November 24, 2009Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 7618966Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.Type: GrantFiled: April 24, 2006Date of Patent: November 17, 2009Assignee: Allergan, Inc.Inventors: June Chen, Simon Pettit, Hans Fliri
-
Patent number: 7612101Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.Type: GrantFiled: April 24, 2006Date of Patent: November 3, 2009Assignee: Allergan, Inc.Inventors: June Chen, Simon Pettit, Hans Fliri
-
Patent number: 7598027Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.Type: GrantFiled: February 23, 2005Date of Patent: October 6, 2009Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Patton E. Garay, Kei Roger Aoki
-
Patent number: 7556817Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region.Type: GrantFiled: September 19, 2006Date of Patent: July 7, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Melvin S. Oka
-
Patent number: 7534863Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: GrantFiled: January 8, 2004Date of Patent: May 19, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7531179Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: May 12, 2009Assignee: Allergan, Inc.Inventor: M. Zouhair Atassi
-
Patent number: 7514088Abstract: The present invention is directed to multivalent Clostridial neurotoxin derivatives having more than one binding domain directed to a cell surface feature of a target cell. Such modified neurotoxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.Type: GrantFiled: March 15, 2006Date of Patent: April 7, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Fernandez-Salas Ester, Joseph Francis, Shengwin Li, Marcella A. Gilmore, Kei Roger Aoki
-
Patent number: 7495069Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.Type: GrantFiled: December 11, 2006Date of Patent: February 24, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
-
Patent number: 7491799Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In some embodiments, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular ailments and pain.Type: GrantFiled: January 14, 2004Date of Patent: February 17, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7462699Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: December 9, 2008Assignees: Allergan, Inc., Baylor College of MedicineInventor: M. Zouhair Atassi
-
Patent number: 7456272Abstract: Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.Type: GrantFiled: August 2, 2007Date of Patent: November 25, 2008Assignee: Allergan, Inc.Inventors: Wei-Jen Lin, Kei Roger Aoki, Lance E. Steward
-
Patent number: 7425338Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: GrantFiled: June 20, 2007Date of Patent: September 16, 2008Assignee: Allergan, Inc.Inventor: Stephen Donovan